Pfizer (NYSE:PFE) Stock Price Down 1.6% – Time to Sell?

Pfizer Inc. (NYSE:PFE) shares fell 1.6% during trading on Tuesday . The stock traded as low as $25.13 and last traded at $25.3550. 43,360,166 shares traded hands during mid-day trading, a decline of 15% from the average session volume of 51,228,027 shares. The stock had previously closed at $25.77.

Analyst Ratings Changes

A number of research firms recently weighed in on PFE. UBS Group restated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 target price on shares of Pfizer in a research report on Wednesday, November 5th. HSBC reiterated a “buy” rating and issued a $29.00 price target on shares of Pfizer in a report on Wednesday. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research note on Wednesday. Finally, Scotiabank initiated coverage on shares of Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.56.

Pfizer Trading Up 0.1%

The company has a market cap of $146.69 billion, a price-to-earnings ratio of 15.00 and a beta of 0.46. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The business’s 50-day simple moving average is $25.15 and its 200-day simple moving average is $24.74.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The business had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 7th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date of this dividend was Friday, November 7th. Pfizer’s payout ratio is 100.00%.

Institutional Trading of Pfizer

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PFE. Brighton Jones LLC grew its stake in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC boosted its holdings in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors grew its position in shares of Pfizer by 4.5% in the first quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 12,294 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 533 shares during the period. HighTower Advisors LLC increased its stake in Pfizer by 4.8% in the first quarter. HighTower Advisors LLC now owns 2,899,841 shares of the biopharmaceutical company’s stock valued at $73,482,000 after purchasing an additional 132,371 shares during the last quarter. Finally, Dagco Inc. purchased a new position in Pfizer during the first quarter worth about $67,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.